Form 4: AbbVie Director Acquires Stock Equivalent Units

AbbVie Director Susan E. Quaggin acquired 67 stock equivalent units, valued at $231.54 each, as part of her director compensation.

Summary

• Susan E. Quaggin, a Director at AbbVie Inc., acquired 67 stock equivalent units on September 30, 2025.
• These units were credited to her account as part of her director fees.
• Each unit was valued at $231.54, totaling an acquisition value of $15,513.18.
• The stock equivalent units are held in a grantor trust and are generally paid in cash at age 65 or upon retirement from the board.
• These units are designed to earn the same return as if the fees were directly invested in AbbVie common stock.
• Following this transaction, Ms. Quaggin beneficially owns a total of 634 stock equivalent units, which includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the alignment of director and shareholder interests through equity-based compensation, though it's a routine transaction with no significant new information.

Positives

• The acquisition of stock equivalent units by a director aligns management's interests with those of shareholders, fostering a shared incentive for company performance.
• The structure of the compensation, linking director fees to stock performance, demonstrates a commitment to long-term value creation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely an insider transaction report.

Industry Context

Insider transactions, particularly those related to routine compensation, are common across publicly traded companies. The acquisition of stock equivalent units by a director is a standard practice to align the interests of board members with long-term shareholder value, reflecting a common corporate governance strategy in the pharmaceutical and biotechnology industry.

Related Party Transactions

• The acquisition of stock equivalent units by Director Susan E. Quaggin as part of her director fees constitutes a related party transaction, aligning her compensation with the company's equity performance.

Stakeholder Impact

• Shareholders: The transaction indicates an alignment of director interests with shareholder value, as the director's compensation is tied to the performance of AbbVie's stock.
• Management: The compensation structure incentivizes the director to contribute to the long-term success and stock performance of the company.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to director compensation. It does not provide new fundamental information about AbbVie's operational performance, financial health, or strategic outlook that would warrant a change in an investment recommendation. The transaction, while positive for aligning interests, is not significant enough in scale to materially impact the stock's valuation or alter an existing investment thesis.

Keywords

AbbVie, ABBV, Insider Transaction, Director Compensation, Stock Equivalent Units, Form 4, Corporate Governance